Related Experiment Video
Updated: Sep 27, 2025

Scanning Electron Microscopy of Macerated Tissue to Visualize the Extracellular Matrix
Published on: June 14, 2016
Critical role of PAFR/YAP1 positive feedback loop in cardiac fibrosis
Tian-Yu Li1, Wei Su1, Liang-Liang Li1
1Department of Pharmacology (State-Province Key Laboratories of Biomedicine-Pharmaceutics of China, Key Laboratory of Cardiovascular Research, Ministry of Education), College of Pharmacy, Harbin Medical University, Harbin, 150081, China.
Insights
Aberrant activation of cardiac fibroblasts drives fibrosis. This study reveals a platelet-activating factor (PAF) and Hippo pathway feedback loop, involving PAF receptor (PAFR) and yes-associated protein 1 (YAP1), as a key driver of cardiac fibrosis and a potential therapeutic target.
Area of Science:
- Cardiovascular Biology
- Molecular Medicine
- Fibrosis Research
Background:
- Cardiac fibrosis, driven by fibroblast activation, is central to heart disease.
- Platelet-activating factor (PAF) and the Hippo pathway are implicated in cardiovascular diseases.
Purpose of the Study:
- To investigate the roles of PAF and the Hippo signaling pathway in cardiac fibrosis.
- To elucidate the molecular mechanisms underlying PAF- and Hippo pathway-mediated cardiac fibrosis.
Main Methods:
- Myocardial infarction (MI) model in mice induced by coronary artery ligation.
- Analysis of cardiac tissue and cultured mouse cardiac fibroblasts.
- Gene silencing using shRNA and conditional gene deletion in transgenic mice.
Main Results:
- Increased expression of Platelet-Activating Factor Receptor (PAFR) and Yes-Associated Protein 1 (YAP1) in MI mouse hearts and Angiotensin II-treated fibroblasts.
- PAF activates YAP1, promoting fibroblast-myofibroblast transition and collagen deposition.
- YAP1 enhances PAFR expression, establishing a positive feedback loop.
- Silencing PAFR or YAP1, or YAP1 deletion in fibroblasts, reduced cardiac fibrosis and improved cardiac function post-MI.
Conclusions:
- A positive feedback loop between PAFR and YAP1 significantly contributes to cardiac fibrosis.
- Targeting the PAFR/YAP1 pathway offers a promising therapeutic strategy for cardiac fibrosis and related heart diseases.
Abstract:
Aberrant activation of cardiac fibroblasts is the main cause and character of cardiac fibrosis, and inhibition of cardiac fibrosis becomes a promising treatment for cardiac diseases. Platelet-activating factor (PAF) and Hippo pathway is recently recognized as key signaling mechanisms in cardiovascular diseases. In this study we explored the potential roles of PAF and Hippo signaling pathway in cardiac fibrosis. Myocardial infarction (MI) was induced in mice by left anterior descending artery ligation. After 28 days, the mice were sacrificed, and the hearts were collected for analyses. We showed that PAF receptor (PAFR) and yes-associated protein 1 (YAP1, a key effector in the Hippo pathway) were significantly increased in the heart of MI mice. Increased expression of PAFR and YAP1 was also observed in angiotensin II (Ang II)-treated mouse cardiac fibroblasts. In mouse cardiac fibroblasts, forced expression of YAP1 increased cell viability, resulted in collagen deposition and promoted fibroblast-myofibroblast transition. We showed that PAF induced fibrogenesis through activation of YAP1 and promoted its nuclear translocation via interacting with PAFR, while YAP1 promoted the expression of PAFR by binding to and activating transcription factor TEAD1. More importantly, silencing PAFR or YAP1 by shRNA, or using transgenic mice to induce the conditional deletion of YAP1 in cardiac fibroblasts, impeded cardiac fibrosis and improved cardiac function in MI mice. Taken together, this study elucidates the role and mechanisms of PAFR/YAP1 positive feedback loop in cardiac fibrosis, suggesting a potential role of this pathway as novel therapeutic targets in cardiac fibrosis.
More Related Videos
Related Concept Videos
Pathophysiology of Heart Failure
Heart Failure II: Pathophysiology
Rheumatic Heart Disease I: Introduction

